Latest News

The trial is evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, AMD, and rare eye diseases.

The Swiss-designed phaco platform provides mobility, simplified workflows, and reduced surgical waste for cataract procedures, according to the company.

OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.

Formerly, the EDOF technology was specifically limited to intraocular lenses.

Patients underwent a full ophthalmologic examination that included optical coherence tomography (OCT), OCT angiography, and biometry.

The Investigational New Drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug delivery, laser therapy, and workflow integration are reshaping earlier, more individualized glaucoma care.

The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD).

Optoretinography is an emerging technology used to test light-evoked photoreceptor activity.

Their conversation focuses on anatomy-driven, individualized approaches and multidisciplinary decision-making for patients with neovascular glaucoma.